Evidence map›Paper›PMID 37669045›Full record

ArticleAnnals of surgery2024

How Does Omitting Additional Surgery After Local Excision Affect the Prognostic Outcome of Patients With High-risk T1 Colorectal Cancer?

Akira Ouchi, Koji Komori, Tajika Masahiro, Kazuhiro Toriyama, Yoshiki Kajiwara, Shiro Oka, Yosuke Fukunaga, Kinichi Hotta, Hiroaki Ikematsu, Shunsuke Tsukamoto and 24 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Annals of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07669298 (Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07669298 narecruitingnot on this mapstarted 2026, after this paper: background citation

Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer: Multicentre Randomised Controlled Trial

TypeinterventionalSponsorMedical University of GdanskRan2026 to 2037Enrolled480ConditionsRectal CancerArmsActive surveillance, Adjuvant chemoradiotherapy
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Competing Mortality Redefines the Net Benefit of Additional Surgery After Endoscopic Resection for T1 Colorectal Cancer in Older Adults.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026
    Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Comment on "How Does Omitting Additional Surgery After Local Excision Affect the Prognostic Outcome of Patients With High-Risk T1 Colorectal Cancer?"Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024
    Article
  13. [Prognosis Analysis of Additional Surgical Treatment for High-Risk T1 Colorectal Cancer Patients After Endoscopic Resection].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 2 countries.

Akira OuchiDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Koji KomoriDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Tajika MasahiroDepartment of Endoscopy, Aichi Cancer Center Hospital, Aichi, Japan.
Kazuhiro ToriyamaDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.
Yoshiki KajiwaraDepartment of Surgery, National Defense Medical College, Tokorozawa, Japan.
Shiro OkaDepartment of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
Yosuke FukunagaDepartment of Colorectal Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kinichi HottaDivision of Endoscopy, Shizuoka Cancer Center, Sunto, Japan.
Hiroaki IkematsuDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Shunsuke TsukamotoDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Shinji NagataDepartment of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Kazutaka YamadaColoproctology Center Takano Hospital, Kumamoto, Japan.
Maki KonnoDepartment of Gastroenterology, Tochigi Cancer Center, Utsunomiya, Japan.
Soichiro IshiharaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Yusuke SaitohDigestive Disease Center, Asahikawa City Hospital, Hokkaido, Japan.
Kenji MatsudaSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Kazutomo TogashiDepartment of Coloproctology, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan.
Megumi IshiguroMedical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan.
Toshio KuwaiDepartment of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Takashi OkuyamaDepartment of Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Akihiro OhuchiDepartment of Gastroenterology, School of Medicine, Kurume University, Fukuoka, Japan.
Shinobu OhnumaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuhiro SakamotoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Tamotsu SugaiDepartment of Molecular Diagnostic Pathology, School of Medicine, Iwate Medical University, Iwate, Japan.
Kenji KatsumataDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.
Hiro-O MatsushitaDigestive Disease Center, Akita Red Cross Hospital, Akita, Japan.
Keisuke NakaiDepartment of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Toshio UraokaDepartment of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Naohiko AkimotoDepartment of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
Hirotoshi KobayashiDepartment of Surgery, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.
Yoichi AjiokaDivision of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Science, Niigata University, Niigata, Japan.
Kenichi SugiharaTokyo Medical and Dental University, Tokyo, Japan.
Hideki UenoDepartment of Surgery, National Defense Medical College, Tokorozawa, Japan.
Study Group for the JSCCR-T study
Aichi Cancer Center · JPHiroshima University Hospital · JPJapanese Foundation For Cancer Research · JPNational Defense Medical College · JPTokyo Medical and Dental University · JPAkita Red Cross Hospital · JPAsahikawa City Hospital · JPFinancial Research (Hungary) · HUFukushima Medical University · JPHiroshima City Asa Citizens Hospital · JPHyogo Medical University · JPIwate Medical University · JPJuntendo University · JPKurume University · JPNational Cancer Center Hospital East · JPNational Hospital Organization · JPNiigata University · JPNippon Medical School · JPShizuoka Cancer Center · JPSocial Insurance Saitama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate how omitting additional surgery after local excision (LE) affects patient outcomes in high-risk T1 colorectal cancer (CRC).

backgroundIt is debatable whether additional surgery should be performed for all patients with high-risk T1 CRC regardless of the tolerability of invasive procedures.

methodsPatients who had received LE for T1 CRC at the Japanese Society for Cancer of the Colon and Rectum institutions between 2009 and 2016 were analyzed. Those who had received additional surgical resection and those who did not were matched one-on-one by the propensity score-matching method. A total of 401 propensity score-matched pairs were extracted from 1975 patients at 27 Japanese Society for Cancer of the Colon and Rectum institutions and were compared.

resultsRegional lymph node metastasis was observed in 31 (7.7%) patients in the LE + surgery group. Comparatively, the incidence of oncologic adverse events was low in the LE-alone group, such as the 5-year cumulative risk of local recurrence (4.1%) or overall recurrence (5.5%). In addition, the difference in the 5-year cancer-specific survival between the LE + surgery and LE-alone groups was only 1.8% (99.7% and 97.9%, respectively), whereas the 5-year overall survival was significantly lower in the LE-alone group than in the LE + surgery group [88.5% vs 94.5%, respectively ( P = 0.002)].

conclusionsThose who had decided to omit additional surgery at the dedicated center for CRC treatment presented a small number of oncologic events and a satisfactory cancer-specific survival, which may suggest an important role of risk assessment regarding nononcologic adverse events to achieve a best practice for each individual with high-risk T1 tumors.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsHumansNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesTreatment Outcome

Identifiers

PMID37669045
OpenAlexW4386438586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.